Möchten Sie immer auf dem neuesten Stand bleiben?

Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash...

Revenue Growth Driving Group to Record EBITDA •Revenue of $186.5 million with organic revenue growth of 6.2%•Record Adjusted EBITDA of $45.4 million, up 17.7% year over year, achieved at a margin of...

A Mobilicom Tier-1 defense customer won a U.S. Department of War (DoW) Program of Record, indicating a potential production scale orders for the next 5 years  Cash and cash equivalents surge 120% to...

AtlasClear Holdings Announces Commencement of Dawson James Clearing Operations

Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 ...

BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated...

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned...

Time-Sensitive: Allegations Focus on Concealed Enterprise Sales Cycle Deterioration MNDY INVESTOR ALERT NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP alerts investors in...

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Institutional investors holding positions in Snowflake Inc. (NYSE: SNOW) during the period June 27, 2023 through February 28, 2024 may wish to evaluate...